DOCSLIB.ORG

Neoplasms – an Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neoplasms – an Overview Volume 3, Issue 12, December 2016 Last Revised: April 2018 Risk Adjustment Coding Academy- Coding Focus Neoplasms – An Overview cells are only found in the place where In ICD‐10‐CM, neoplasms are located in they first formed and have not spread3. chapter 2 of the tabular index, under the following code categories5: Benign and Other Neoplasms C00‐C96 Malignant neoplasms, Benign neoplasms are tumors that have primary or secondary by site been determined to be noncancerous. D00‐D09 In situ neoplasms They are localized and have limited D10‐D36, D3A Benign neoplasm potential to grow or invade as well as D37‐D38 Neoplasms uncertain having well differentiated cells. Some behavior, polycythemia vera common types of benign neoplasms are and myelodysplastic syndromes adenomas, lipomas and hemangiomas. D49 Neoplasms unspecified When the behavior of a tumor cannot be behavior The term neoplasm refers to an predicted through pathology, it is called abnormal growth of tissue that occurs a neoplasm of uncertain behavior. These In addition to the tabular index, both when cells divide more than they should are neoplasms which are currently ICD‐9‐CM and ICD‐10‐CM contain a or when cells do not die as they should. benign but have characteristics that neoplasm table that provides a listing of Neoplasms, sometimes referred to as make it possible for the tumor to neoplasms by site, which can then be tumors, are classified mainly by site and become malignant. cross referenced by the aforementioned then further distinguished based upon behavior types. As always, accurate One final category is available for medical record documentation is their behavior. The two main unspecified neoplasm, which is used designations are malignant (or essential for correct diagnosis code when pathology has not yet determined assignment. cancerous) and benign (or non‐ the specific behavior of the neoplasm. cancerous)1. Resources: Coding Guidance Malignant Neoplasms 1 National Cancer Institute (n.d.) NCI There are multiple diagnosis code Dictionary of Cancer Terms. Retrieved Malignant neoplasms are tumors which possibilities for neoplasms, which are November 28, 2016 from cancer.gov are usually irregularly shaped and have based on anatomical site or location and 2 National Cancer Institute (n.d.) poorly differentiated cells that grow or behavior. In ICD‐9‐CM, neoplasm codes Metastatic Cancer. Retrieved November invade other areas and metastasize. were found in chapter 2 of the tabular 28, 2016 from cancer.gov Malignant primary neoplasms refer to index, under the following code 3 Cancer Treatment Centers of America cancerous tumors that originated within categories4: (2015). Cancer in Situ. Retrieved the anatomical site. Malignant secondary 140‐199 Malignant neoplasms, November 28, 2016 from neoplasms refer to cancerous tumors primary or secondary by site that spread to a new site from a primary cancercenter.com 200‐208 Malignant neoplasms site. When this occurs, the primary 4 Hart, A. C., Stegman, M. S., & Ford, B. of lymphatic and hematopoietic cancer is said to be metastatic2. For (2011). ICD‐9‐CM for physicians, volumes tissue example, lung cancer metastatic to the 1 & 2: 2012 professional: International 209 Neuroendocrine tumors bone has a primary site of the lung which Classification of Diseases, 9th revision, 210‐229 Benign neoplasms has now spread to the secondary Clinical Modification. Eden Prairie, MN: 230‐234 Carcinoma in situ location of the bone. OptumInsight. 235‐238 Neoplasm of uncertain 5 Anita Schmidt, K.K., &, P.W. (2016). ICD‐10‐ Another malignant neoplasm type is an behavior CM Expert for Physicians. Optum360 early stage of cancer known as in situ. 239 Neoplasms unspecified Cancer in situ means that the abnormal Coverage provided by Amerigroup, Inc. Reference the ICD-10-CM codebook, CMS-HCC Risk Adjustment Model V23, and AHA Coding Clinic for complete code sets and official coding guidance. It is not guaranteed that the information supplied is without defect. Any redistribution or other use is strictly forbidden. Y0114_16_30390_I_01/03/2017 .
Load more

Recommended publications
  • Medical Oncology and Breast Cancer
    The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 MEDICAL ONCOLOGY Treatment for breast cancer is multidisciplinary. The primary physicians with whom you may meet as part of your care are the medical oncologist, the breast surgeon, and often the radiation oncologist. A list of these specialty physicians will be provided to you. Each provider works with a team of caregivers to ensure that every patient receives high quality, personalized, breast cancer care. The medical oncologist specializes in “systemic therapy”, or medications that treat the whole body. For women with early stage breast cancer, systemic therapy is often recommended to provide the best opportunity to prevent breast cancer from returning. SYSTEMIC THERAPY Depending on the specific characteristics of your cancer, your medical oncologist may prescribe systemic therapy. Systemic therapy can be hormone pills, IV chemotherapy, antibody therapy (also called “immunotherapy”), and oral chemotherapy; sometimes patients receive more than one type of systemic therapy. Systemic therapy can happen before surgery (called “neoadjuvant therapy”) or after surgery (“adjuvant therapy”). If appropriate, your breast surgeon and medical oncologist will discuss the benefits of neoadjuvant and adjuvant therapy with you. As a National Comprehensive Cancer Network (NCCN) Member Institution, we are dedicated to following the treatment guidelines that have been shown to be most effective. We also have a variety of clinical trials that will help us find better ways to treat breast cancer. Your medical oncologist will recommend what treatment types and regimens are best for you. The information used to make these decisions include: the location of the cancer, the size of the cancer, the type of cancer, whether the cancer is invasive, the grade of the cancer (a measure of its aggressiveness), prognostic factors such as hormone receptors and HER2 status, and lymph node involvement.
    [Show full text]
  • Exposure to Carcinogens and Work-Related Cancer: a Review of Assessment Methods
    European Agency for Safety and Health at Work ISSN: 1831-9343 Exposure to carcinogens and work-related cancer: A review of assessment methods European Risk Observatory Report Exposure to carcinogens and work-related cancer: A review of assessment measures Authors: Dr Lothar Lißner, Kooperationsstelle Hamburg IFE GmbH Mr Klaus Kuhl (task leader), Kooperationsstelle Hamburg IFE GmbH Dr Timo Kauppinen, Finnish Institute of Occupational Health Ms Sanni Uuksulainen, Finnish Institute of Occupational Health Cross-checker: Professor Ulla B. Vogel from the National Working Environment Research Centre in Denmark Project management: Dr Elke Schneider - European Agency for Safety and Health at Work (EU-OSHA) Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers, or these calls may be billed. More information on the European Union is available on the Internet ( 48TU http://europa.euU48T). Cataloguing data can be found on the cover of this publication. Luxembourg: Publications Office of the European Union, 2014 ISBN: 978-92-9240-500-7 doi: 10.2802/33336 Cover pictures: (clockwise): Anthony Jay Villalon (Fotolia); ©Roman Milert (Fotolia); ©Simona Palijanskaite; ©Kari Rissa © European Agency for Safety and Health at Work, 2014 Reproduction is authorised provided the source is acknowledged. European Agency for Safety and Health at Work – EU-OSHA 1 Exposure to carcinogens and work-related cancer:
    [Show full text]
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • INTRINSIC FACTORS in the ETIOLOGY of NEOPLASMS' It Is
    INTRINSIC FACTORS IN THE ETIOLOGY OF NEOPLASMS' CARL V. WELLER, MS., M.D. (From the Department of Pathology, University of Michigan) It is as true as it is trite that the cause of disease is never a single factor. Two elements always enter into etiology. One of these is inherent in the germ plasm of the individual; the other brought to bear upon the organism from beyond the confines of the germinal elements from which it has devel- oped. Better than internal and external, endogenous and exogenous, or con- stitutional and environmental, to designate these two groups of factors, are the terms intrinsic and extrinsic. Practical experience directs us to seek the relative importance of intrinsic and extrinsic factors whenever the causation of disease is studied, and we find that the two ingredients may be combined in every possible proportion. At one end of the series are diseases such as deaf mutism, transmitted as a simple recessive, in which the intrinsic element almost crowds out all other considerations. In the recessively sex-linked hemophilia, again the intrinsic element is so prominent that we see at once the mendelian significance of the process, although the bleeder may not be made known until the extrinsic factor, trauma, opens his blood vessels. The asthenic, dolichomorphic bodily configuration, which marks the phthisical habitus, is a familial character and therefore intrinsic, but it conditions infection by the tubercle bacillus in such a way as to give it serious or even lethal possibilities. When we consider syphilis, we find that the Treponema is no respecter of genetic constitution, yet sex and race may modify the character of the disease.
    [Show full text]
  • Updates in Molecular Pathology of Central Nervous System Gliomas in Adults
    UPDATES IN ONCOLOGY: PART 2 Updates in Molecular Pathology of Central Nervous System Gliomas in Adults MICHAEL PUNSONI, MD; JOHN E. DONAHUE, MD; HEINRICH D. ELINZANO, MD; TIMOTHY KINSELLA, MD 17 19 EN ABSTRACT Epidemiology Central nervous system (CNS) tumors are a heteroge- The incidence of CNS malignancies has been increasing. neous group of neoplasms divided into two broad cate- Most commonly, CNS tumors arise from glial cells, partic- gories, glial and non-glial. Non-glial tumors are derived ularly astrocytes and oligodendrocytes. Gliomas account from such diverse structures as the pineal gland, menin- for approximately 77% of primary malignant brain tumors ges, germ cells, and hematopoietic cells, as well as metas- (3). Most patients present between the fifth and seventh tases. Primary glial neoplasms, or those which originate decade of life. High-grade tumors are more common than from astrocytes, oligodendrocytes, or ependymal cells, low-grade and present a high risk of morbidity and mortal- include astrocytomas, oligodendrogliomas, ependymo- ity. The World Health Organization (WHO) in 2000 formu- mas, and mixed gliomas. Each entity has a unique mor- lated a classification system based on histologic findings phology and pattern of biologic behavior which portends that is used to stratify brain tumors into prognostic grades. a distinct prognosis and outcome. Individual outcomes High-grade gliomas (WHO grade III and IV) are most com- show some variability based on tumor location and age of monly seen in middle-aged to older adults, while grade II symptom onset; however, the underlying aggressiveness astrocytomas mainly affect younger adults. Management for of the tumor often dictates the time course of the disease.
    [Show full text]
  • Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary
    Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s.
    [Show full text]
  • 797 Circulating Tumor DNA and Circulating Tumor Cells for Cancer
    Medical Policy Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History • Endnotes Policy Number: 797 BCBSA Reference Number: 2.04.141 Related Policies Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer, #336 Policy1 Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Plasma-based comprehensive somatic genomic profiling testing (CGP) using Guardant360® for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) is considered MEDICALLY NECESSARY when the following criteria have been met: Diagnosis: • When tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), AND • When prior results for ALL of the following tests are not available: o EGFR single nucleotide variants (SNVs) and insertions and deletions (indels) o ALK and ROS1 rearrangements o PDL1 expression. Progression: • Patients progressing on or after chemotherapy or immunotherapy who have never been tested for EGFR SNVs and indels, and ALK and ROS1 rearrangements, and for whom tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP), OR • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs). If no genetic alteration is detected by Guardant360®, or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered. Other plasma-based CGP tests are considered INVESTIGATIONAL. CGP and the use of circulating tumor DNA is considered INVESTIGATIONAL for all other indications. 1 The use of circulating tumor cells is considered INVESTIGATIONAL for all indications.
    [Show full text]
  • Connections Between Warburg's and Szentgyorgyi's Approach About The
    Research iMedPub Journals Journal of Neoplasm 2017 http://www.imedpub.com/ ISSN 2576-3903 Vol.1 No.2:8 DOI: 10.217672576-3903.100008 Connections between Warburg’s and Szentgyorgyi’s Approach about the Causes of Cancer Szigeti GP1, Szasz O2 and Hegyi G3 1Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Hungary 2Department of Biotechnics, St. Istvan University, Hungary 3Department of Complementary and Alternative Medicine, University of Pecs, Hungary Corresponding author: Gabriella Hegyi, Department of Complementary and Alternative Medicine, University of Pecs, Hungary, Tel: +36 30 922-5347; E-mail: [email protected] Rec date: November 30, 2016; Acc date: December 26, 2016; Pub date: December 30, 2016 Citation: Szigeti GP, Szasz O, Hegyi G. Connections Between Warburg’s and Szentgyorgyi’s Approach About Causes of Cancer. J Neoplasm. 2017, 1: 2. to the environmental, diet and habit origins of malignant Abstract diseases [21-23]. Most widely, cancer is believed to be an abnormal tissue Numerous theories and hypotheses are published about triggered by a gene mutation. However, the proto-oncogene the causes of cancer and its hallmarks. Two remarkable and the oncogene appear not only in cancerous cases [24], but principles were established and debated for a long time. with pregnancy [25], with embryogenesis [26,27], with the The first is the Warburg-effect, which based on healing of wounds [28] and with the synthesis of growth mitochondrial dysfunction, connected to the intensive factors [29]. Oncogenes show a great variety of anti-apoptotic metabolic activity of the malignancy. The other is the functions with the cells taking part in the wound-healing [30].
    [Show full text]
  • Injury and Cancer
    Case Western Reserve Law Review Volume 5 Issue 2 Article 4 1954 Injury and Cancer Lester Adelson Follow this and additional works at: https://scholarlycommons.law.case.edu/caselrev Part of the Law Commons Recommended Citation Lester Adelson, Injury and Cancer, 5 W. Rsrv. L. Rev. 150 (1954) Available at: https://scholarlycommons.law.case.edu/caselrev/vol5/iss2/4 This Article is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It has been accepted for inclusion in Case Western Reserve Law Review by an authorized administrator of Case Western Reserve University School of Law Scholarly Commons. [Winter Injury and Cancer by Lester Adelson, M.D. WITH LEGAL ANNOTATIONS BY OLIVER SCHROEDER, JR.* INTRODUCTION THE WORD "cancer" is one which is charged with emotion and fear, carrying with it implications of prolonged disability and slow, certain and painful death.' In considering and discussing the subject of cancer, diffi- culties frequently arise, not because not enough is known, but because so much is known that-is incorrect and untrue. A vast fund of misinformation and false information mis- leads the unwary stranger THE AUTHOR (A.B., 1935, Harvard Univer- and the uncritical observer. sity; M.D., 1939, Tufts College Medical School) is Chief Deputy Coroner and Patholo- Cancer is the second gist at the Coroner's Office, Cuyahoga County, leading cause of death, and Ohio, and Assistant Professor of Legal Medi- problems which arise in cine at the School of Medicine of Western Reserve University. connection with it are seen frequently.
    [Show full text]
  • Hematopoietic and Lymphoid Neoplasm Coding Manual
    Hematopoietic and Lymphoid Neoplasm Coding Manual Effective with Cases Diagnosed 1/1/2010 and Forward Published August 2021 Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER Margaret (Peggy) Adamo, BS, AAS, RHIT, CTR, NCI SEER Lois Dickie, CTR, NCI SEER Serban Negoita, MD, PhD, CTR, NCI SEER Suggested citation: Ruhl J, Adamo M, Dickie L., Negoita, S. (August 2021). Hematopoietic and Lymphoid Neoplasm Coding Manual. National Cancer Institute, Bethesda, MD, 2021. Hematopoietic and Lymphoid Neoplasm Coding Manual 1 In Appreciation NCI SEER gratefully acknowledges the dedicated work of Drs, Charles Platz and Graca Dores since the inception of the Hematopoietic project. They continue to provide support. We deeply appreciate their willingness to serve as advisors for the rules within this manual. The quality of this Hematopoietic project is directly related to their commitment. NCI SEER would also like to acknowledge the following individuals who provided input on the manual and/or the database. Their contributions are greatly appreciated. • Carolyn Callaghan, CTR (SEER Seattle Registry) • Tiffany Janes, CTR (SEER Seattle Registry) We would also like to give a special thanks to the following individuals at Information Management Services, Inc. (IMS) who provide us with document support and web development. • Suzanne Adams, BS, CTR • Ginger Carter, BA • Sean Brennan, BS • Paul Stephenson, BS • Jacob Tomlinson, BS Hematopoietic and Lymphoid Neoplasm Coding Manual 2 Dedication The Hematopoietic and Lymphoid Neoplasm Coding Manual (Heme manual) and the companion Hematopoietic and Lymphoid Neoplasm Database (Heme DB) are dedicated to the hard-working cancer registrars across the world who meticulously identify, abstract, and code cancer data.
    [Show full text]
  • Cancer Risk Assessment and Cancer Prevention: Promises and Challenges
    CommentaryCancer Prevention Research Cancer Risk Assessment and Cancer Prevention: Promises and Challenges Brian J. Reid “Acquired genetic lability permits stepwise selection of variant cancer itself, but morphologic assessment may be limited in its sublines and underlies tumor progression” (1). ability to distinguish asymptomatic indolent conditions from Despite intense efforts to cure cancers through advances in those that will progress to advanced malignancies and death staging, surgery, chemo- and radiation therapy, treatment of (3–5, 13). Examining cancer from an evolutionary perspective most advanced, symptomatic epithelial malignancies con- can open new approaches for cancer risk assessment, diagnosis, tinues to be challenging, and age-adjusted cancer mortality therapy and prevention. The evolution of multicellular organ- in the United States has decreased by only 5%since 1950 isms has been accompanied by constraint of cellular evolution, (2). The clinical course of treated cancer patients all too often and cancer represents a breakdown of the mechanisms that culminates in relapse and death. Ironically, growing evidence suppress cellular evolution. Cairns hypothesized that the archi- also suggests that many patients with premalignancy or even tecture of proliferating epithelial tissues would suppress tumor malignancy follow benign courses and die far more often of formation by restricting and sequestering stem cells in epithe- non-cancer causes than of cancer (3–5). These paradoxical phe- lial proliferative units, for example, at the base of intestinal nomena form the dilemma of early detection-underdetection crypts (14). Opportunities for competition between variants of life-threatening early disease and overdetection of indolent that might arise would be restrained by shedding differentiated early disease.
    [Show full text]
  • Cancer-Related Terminology Used by a Healthcare Team
    FEATURE IJPC GLossary OF THE MOST COMMON CANCER-RELated TERMINOLOGY USED BY A HEALthcare TEAM ADRENAL GLAND: Two glands, located near the kidneys, CANCER: A general term for more than 100 diseases in which ab- which produce hormones that control metabolism, fluid balance, normal cells grow out of control. Also used to refer to a malignant and blood pressure. They also produce small amounts of “male” (cancerous) tumor. hormones (androgens) and “female” hormones (estrogens and progesterone). CARCINOGEN: Any substance that causes cancer or helps cancer grow (e.g., tobacco smoke contains many carcinogens that greatly ADVANCED cancer: A general term describing later stages increase the risk of lung cancer) of cancer (usually stage 3 or 4) in which the disease has spread from the primary site (where it started) to other parts of the body. Catheter: A thin, flexible tube used to introduce fluids into the When the cancer has spread only to nearby areas, it is called locally body or to remove fluids from the body advanced. If it has spread to distant parts of the body, it is called metastatic. CELL: The basic unit of which all living things are made. Cells re- place themselves by dividing and forming new cells. The processes ALOPECIA: Hair loss, usually temporary. This is a side effect of that control the formation of new cells and the death of old cells are some chemotherapy drugs or radiation. disrupted in cancer. ANEMIA: Having too few red blood cells (“low blood”). This may CENTRAL VENOUS catheter (CVC): A special thin, flex- be a complication of the cancer or a side effect of treatment.
    [Show full text]